See more : Evans Bancorp, Inc. (EVBN) Income Statement Analysis – Financial Results
Complete financial analysis of Astria Therapeutics, Inc. (ATXS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Astria Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Teleste Corporation (TLT1V.HE) Income Statement Analysis – Financial Results
- Voltamp Transformers Limited (VOLTAMP.BO) Income Statement Analysis – Financial Results
- Riddhi Corporate Services Limited (RIDDHICORP.BO) Income Statement Analysis – Financial Results
- Scan Inter Public Company Limited (SCN.BK) Income Statement Analysis – Financial Results
- GoMax Electronics Co., Ltd. (6512.TWO) Income Statement Analysis – Financial Results
Astria Therapeutics, Inc. (ATXS)
About Astria Therapeutics, Inc.
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 500.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 26.00K | 119.00K | 0.00 | 395.00K | 202.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | -26.00K | -119.00K | 500.00K | -395.00K | -202.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 57.33M | 34.26M | 15.55M | 25.59M | 18.32M | 17.04M | 18.68M | 25.45M | 23.03M | 15.69M | 13.99M | 12.41K |
| General & Administrative | 25.70M | 19.24M | 14.81M | 11.85M | 8.77M | 9.33M | 8.91M | 10.11M | 8.63M | 6.00M | 4.13M | 3.27K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 718.00 |
| SG&A | 25.70M | 19.24M | 14.81M | 11.85M | 8.77M | 9.33M | 8.91M | 10.11M | 8.63M | 6.00M | 4.13M | 3.98K |
| Other Expenses | 0.00 | -55.00K | -58.00K | -101.00K | -50.00K | 176.00K | 32.00K | 93.00K | 7.00K | 3.00K | 1.00K | 0.00 |
| Operating Expenses | 83.03M | 53.50M | 30.36M | 37.44M | 27.09M | 26.37M | 27.59M | 35.56M | 31.66M | 21.68M | 18.12M | 15.67K |
| Cost & Expenses | 83.03M | 53.50M | 30.36M | 37.44M | 27.09M | 26.37M | 27.59M | 35.56M | 31.66M | 21.68M | 18.12M | 15.67K |
| Interest Income | 10.20M | 1.72M | 122.00K | 236.00K | 845.00K | 425.00K | 160.00K | 242.00K | 0.00 | 0.00 | 0.00 | 4.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 100.00K | 462.00K | 837.00K | 978.00K | 206.00K | 0.00 | 0.00 |
| Depreciation & Amortization | -15.20M | 228.49K | -164.62M | 26.00K | 26.00K | 119.00K | 304.00K | 395.00K | 202.00K | 248.00K | 320.00K | 327.00 |
| EBITDA | -83.03M | -53.50M | -194.98M | -37.44M | -26.27M | -25.65M | -26.60M | -34.83M | -31.46M | -21.43M | -17.80M | -15.34M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5,319.60% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -83.03M | -53.50M | -194.98M | -37.44M | -27.09M | -26.37M | -27.09M | -35.56M | -31.66M | -21.68M | -18.12M | -15.67K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5,418.80% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 10.14M | 1.67M | 64.00K | 135.00K | 795.00K | 501.00K | -270.00K | -502.00K | -971.00K | -203.00K | 1.00K | 4.00 |
| Income Before Tax | -72.89M | -51.83M | -194.91M | -37.30M | -26.29M | -25.87M | -27.36M | -36.06M | -32.63M | -21.88M | -18.12M | -15.67K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5,472.80% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.67M | -164.74M | -236.00K | -50.00K | 601.00K | 494.00K | 930.00K | 783.00K | 209.00K | 0.00 | 0.00 |
| Net Income | -72.89M | -50.17M | -30.17M | -37.06M | -26.24M | -25.87M | -27.36M | -36.06M | -32.63M | -21.88M | -18.12M | -15.67K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5,472.80% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.42 | -3.43 | -3.38 | -12.12 | -14.06 | -30.71 | -75.73 | -133.31 | -243.45 | -151.53 | -125.45 | -0.11 |
| EPS Diluted | -2.42 | -3.43 | -3.38 | -12.12 | -14.06 | -30.71 | -75.73 | -133.31 | -243.45 | -151.53 | -125.45 | -0.11 |
| Weighted Avg Shares Out | 30.12M | 14.62M | 8.93M | 3.06M | 1.87M | 842.47K | 361.36K | 270.50K | 134.03K | 144.42K | 144.42K | 144.42K |
| Weighted Avg Shares Out (Dil) | 30.12M | 14.62M | 8.93M | 3.06M | 1.87M | 842.47K | 361.36K | 270.50K | 134.03K | 144.42K | 144.42K | 144.42K |
Astria Therapeutics to Present Patient Survey Data at Upcoming 2023 HAEi Regional EMEA Conference
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that it will present information regarding patient preference...
Astria Therapeutics Reports Second Quarter Financial Results and Provides a Corporate Update
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today reported financial results for the second quarter ended June...
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, granted stock options to purchase 174,000 shares of Astria's common stock...
Astria (ATXS) Rises 5% on Fast Track Tag for Angioedema Drug
Astria (ATXS) gets FDA's fast track tag for its lead product candidate, STAR-0215, which is currently being evaluated in an early-mid-stage study to treat hereditary angioedema. The stock rises 5%.
Astria Therapeutics Receives Fast Track Designation for STAR-0215 for the Treatment of Hereditary Angioedema
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that the STAR-0215 development program has received Fast...
Astria Therapeutics Names John Ruesch as Senior Vice President, Pharmaceutical Sciences and Technical Operations
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that it has named John Ruesch as Senior...
Astria Therapeutics to Present Patient Survey Data at Upcoming 2023 US HAEA National Summit
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that it will present information regarding patient preference...
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, granted stock options to purchase 60,000 shares of Astria's common stock...
Astria Therapeutics to Present STAR-0215 at the 13th C1-Inhibitor Deficiency and Angioedema Workshop
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that it will present information on STAR-0215 and its...
Astria: Biotech To Watch With Proof Of Concept Established For HAE
Astria: Biotech To Watch With Proof Of Concept Established For HAE.
Source: https://incomestatements.info
Category: Stock Reports